Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 6/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ELOVL6 | Q9H5J4 | 2/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2470044 | 0.89 | ELOVL6 (0.42) | MDM2MEN1KMT2AIDO1ELOVL6 | |
| SCHEMBL2471187 | 0.88 | MDM2 (0.44) | MDM2MEN1KMT2AIDO1CYP2D6 | |
| SCHEMBL2469467 | 0.87 | HTT (0.38) | MDM2KMT2AMAPTPDK2 | |
| SCHEMBL27311876 | 0.84 | MDM2 (0.55) | MDM2MEN1KMT2AIDO1MAPT | |
| SCHEMBL11388713 | 0.84 | MDM2 (0.46) | MDM2MEN1KMT2AIDO1CYP2D6 | |
| SCHEMBL2469609 | 0.83 | MAPT (0.38) | IDO1MAPTELOVL6PDK2 | |
| SCHEMBL11882562 | 0.83 | MDM2 (0.54) | MDM2MEN1KMT2AIDO1CYP2D6 | |
| SCHEMBL13087801 | 0.83 | MAPT (0.36) | MEN1KMT2AIDO1MAPTELOVL6 | |
| SCHEMBL2471501 | 0.82 | CYP46A1 (0.38) | MEN1KMT2AIDO1MAPTELOVL6 | |
| SCHEMBL2472692 | 0.81 | MAPT (0.37) | MEN1KMT2AIDO1MAPTELOVL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858520-B1 | QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2011-10-05 | — | — | EP | disclosed |
| EP-1858520-B1 | QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20100261741-A1 | Quinazolinone T-Type Calcium Channel Antagonists | MERCK (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261741-A1 | Quinazolinone T-Type Calcium Channel Antagonists | MERCK (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261741-A1 | Quinazolinone T-Type Calcium Channel Antagonists | MERCK (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100210671-A1 | Quinazolinone T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME CORP. | 2010-08-19 | — | — | US | disclosed |
| US-20100210671-A1 | Quinazolinone T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME CORP. | 2010-08-19 | — | — | US | disclosed |
| US-20100210671-A1 | Quinazolinone T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME CORP. | 2010-08-19 | — | — | US | disclosed |
| US-7745452-B2 | Quinazolinone T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745452-B2 | Quinazolinone T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-06-29 | — | — | US | disclosed |
| EP-2175725-A1 | QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009009015-A1 | QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009009015-A1 | QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| US-20080167329-A1 | Quinazolinone T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2008-07-10 | — | — | US | disclosed |
| US-20080167329-A1 | Quinazolinone T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2008-07-10 | — | — | US | disclosed |
| EP-1858520-A2 | QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS | Merck & Co., Inc. (US) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006098969-A2 | QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006098969-A2 | QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261741-A1 | Quinazolinone T-Type Calcium Channel Antagonists | CACNA1I, CACNA1G, CACNA1H | MDM2 3494/4885MEN1 1218/4885KMT2A 3946/4885 |
| US-20080167329-A1 | Quinazolinone T-Type Calcium Channel Antagonists | CACNA1I, CACNA1G, CACNA1H | MDM2 3494/4885MEN1 1218/4885KMT2A 3946/4885 |
| US-20100210671-A1 | Quinazolinone T-Type Calcium Channel Antagonists | CACNA1I, CACNA1G, CACNA1H | MDM2 3494/4885MEN1 1218/4885KMT2A 3946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.